Press release
Dexcom G7 is Now the Most Accurate, Smallest, Easy-to-Use CGM Connected to the Tandem t:slim X2 Insulin Pump
With more than 10 years of pioneering CGM market leadership in AID integration, Dexcom is the most studied CGM brand with AID capabilities and the clear
About this update from Dexcom, Inc.
[{"type":"text","content":"\n\nWith more than 10 years of pioneering CGM market leadership in AID integration, Dexcom is the most studied CGM brand with AID capabilities and the clear choice for powering AID systems3,4\n\n\n\nThe clinically meaningful health outcomes that result from using the t:slim X2 insulin pump with Control-IQ technology are proven only when the system is connected to Dexcom CGM technology5\n\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nDexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects with the t:slim X2™ insulin pump by Tandem Diabetes Care in the United States, marking the first AID integration with the Dexcom G7 CGM, the world’s most accurate1,2 CGM system.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231206143334/en/Dexcom G7 CGM now connects with the t:slim X2™ insulin pump by Tandem Diabetes Care in the U.S. (Photo: Business Wire)\n“There’s a reason Dexcom is the undisputed leader in CGM connectivity and the clear choice for AID systems,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “We pioneered industry-leading CGM connectivity more than a decade ago and are the only CGM company to have safely powered AID systems for more than 1 million patient years of cumulative use. The clinically meaningful health outcomes that result from using the t:slim X2 insulin pump with Control-IQ technology are proven only when the system is connected to Dexcom CGM technology.”\n\n\nFurther solidifying Dexcom as the most studied CGM brand with AID capabilities, new results from the COMISAIR seven-year follow up – the longest prospective real-world CGM study ever conducted – showed significant and continued reduction of HbA1c as well as a lower risk of the development or progression of diabetic retinopathy associated with the use of real-time CGM by people with Type 1 diabetes.6 Additionally, the COMISAIR seven-year follow up demonstrated further substantial reduction in HbA1c when Dexcom CGM is connected to the Tandem t:slim X2 insulin pump with Control-IQ technology. 6\n\n\n“When AID systems are used in conjunction with real-time CGM, people with diabetes experience more time in range, fewer incidences of...